Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 128.02 -0.61% -0.78
ALXN closed up 1.23 percent on Tuesday, May 21, 2019, on 84 percent of normal volume.
8 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ALXN trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction -0.61%
Gapped Down Weakness 0.62%
Lower Bollinger Band Touch Weakness 0.62%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.20%
NR7 Range Contraction -2.20%
Multiple of Ten Bullish Other -2.20%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.57%
Multiple of Ten Bullish Other -2.57%
Up 3 Days in a Row Strength -2.57%
Stochastic Reached Oversold Weakness -0.30%

Older signals for ALXN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Medicine Biopharmaceutical Medical Specialties Organ Systems Healthcare Providers Paroxysmal Nocturnal Hemoglobinuria Metabolic Disorders Acquired Hemolytic Anemia Inflammatory Disorders Myasthenia Gravis Alexion Pharmaceuticals Atypical Hemolytic Uremic Syndrome Genetic Disease Hemolytic Uremic Syndrome Kidney Transplant Renal Transplant
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 21 Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
May 20 3 Reasons Growth Investors Will Love Alexion (ALXN)
May 19 Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
May 17 Achillion's ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket
May 16 ALXN or ALKS: Which Is the Better Value Stock Right Now?
May 13 Alexion to Present at the RBC Capital Markets Annual Healthcare Conference
May 13 Alexion to Present at the UBS Global Healthcare Conference
May 13 Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
May 13 Alexion Pharmaceuticals, Inc. (ALXN): Sound Shore Says the Pharmaceutical Company is Driving Innovation
May 9 What Makes Alexion (ALXN) a New Buy Stock
See more ALXN news...
Indicators
Indicator Value
52 Week High 141.86
52 Week Low 92.56
Average Volume 1,281,355
200-Day Moving Average 123.5166
50-Day Moving Average 133.9142
20-Day Moving Average 132.236
10-Day Moving Average 129.77
Average True Range 3.9247
ADX 19.4
+DI 12.92
-DI 24.9188
Chandelier Exit (Long, 3 ATRs ) 125.7459
Chandelier Exit (Short, 3 ATRs ) 137.2541
Upper Bollinger Band 138.7464
Lower Bollinger Band 125.7256
Percent B (%b) 0.24
BandWidth 9.846638
MACD Line -1.4539
MACD Signal Line -1.0171
MACD Histogram -0.4368
Fundamentals Value
Market Cap 28.75 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 55.76
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 132.00
Resistance 3 (R3) 131.90 130.73 131.46
Resistance 2 (R2) 130.73 129.92 130.78 131.28
Resistance 1 (R1) 129.77 129.42 130.25 129.87 131.11
Pivot Point 128.60 128.60 128.85 128.65 128.60
Support 1 (S1) 127.64 127.79 128.12 127.74 126.49
Support 2 (S2) 126.47 127.29 126.52 126.32
Support 3 (S3) 125.51 126.47 126.14
Support 4 (S4) 125.61